## Edwards Lifesciences Faces Class Action Lawsuit Over Alleged Misleading Statements
Robbins Geller Rudman & Dowd LLP, a leading law firm specializing in investor rights, has announced a class action lawsuit against Edwards Lifesciences Corporation (EW). The lawsuit alleges that the company, a prominent provider of medical devices for structural heart disease and critical care monitoring, misled investors about its financial performance and growth prospects.
The class action lawsuit, filed in the United States District Court for the Central District of California, covers investors who purchased Edwards Lifesciences securities between February 6, 2024, and July 24, 2024. The lawsuit alleges that during this period, Edwards Lifesciences made false and misleading statements about the growth potential of its core product, Transcatheter Aortic Valve Replacement (TAVR). TAVR is a minimally invasive procedure used to replace a damaged aortic valve, a critical component of the heart.
The lawsuit claims that Edwards Lifesciences created a false impression of its financial health and future growth, while downplaying potential risks from seasonality and broader economic factors. Specifically, the lawsuit alleges that the company:
*
Overstated the growth of its TAVR product:
The lawsuit alleges that Edwards Lifesciences misrepresented the anticipated growth of TAVR procedures, claiming that the company’s “patient activation activities” would effectively reach a large population in need of the procedure. However, the lawsuit alleges that these efforts failed to achieve the desired results.*
Downplayed the risks associated with newer heart therapies:
The lawsuit alleges that Edwards Lifesciences overly emphasized hospital reliance on TAVR procedures, minimizing the potential impact of newer, innovative structural heart therapies that might challenge TAVR’s market share.The lawsuit further alleges that on July 24, 2024, Edwards Lifesciences disclosed second-quarter 2024 TAVR results that fell short of expectations, leading the company to lower its financial projections for TAVR for the remainder of the year. This news triggered a significant drop in Edwards Lifesciences’ stock price, falling over 31% on the day of the announcement, according to the lawsuit.
Lead Plaintiff Process and Investor Rights
The lawsuit is seeking to appoint a lead plaintiff, an investor who represents the interests of all other investors in the class action. The lead plaintiff will have the authority to direct the lawsuit and select a law firm to represent the class. Investors who purchased Edwards Lifesciences securities during the Class Period have until December 13, 2024, to seek appointment as lead plaintiff.
Robbins Geller Rudman & Dowd LLP encourages investors who have suffered losses during this period to contact the firm to learn more about their rights. The firm has a long history of representing investors in securities fraud cases and has secured billions of dollars in recoveries for clients.
Investors can contact Robbins Geller at 800/449-4900 or via email at info@rgrdlaw.com. More information about the lawsuit is available on the firm’s website: [https://www.rgrdlaw.com/cases-edwards-lifesciences-corporation-class-action-lawsuit-ew.html](https://www.rgrdlaw.com/cases-edwards-lifesciences-corporation-class-action-lawsuit-ew.html)
About Robbins Geller
Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. The firm has consistently been recognized for its success in recovering significant monetary relief for investors. In the last ten years, the firm has secured the most monetary relief for investors in securities class action cases, according to ISS Securities Class Action Services rankings. With 200 lawyers in 10 offices, Robbins Geller is a prominent player in the field of investor rights advocacy.